Ad hoc releases

Please find below Evotec's most recent ad hoc releases according to Article 17 European Market Abuse Regulation (MAR).

 

2021
Evotec SE Announces Placement of its Public Offering of American Depositary Shares
Hamburg, Germany, November 3, 2021

Evotec SE’s management board today decided – with the approval of its supervisory board – on the volume and the issue price of its public offering of American Depositary Shares (“ADSs”). The offering will produce gross proceeds of $ 435,000,000 from the sale of 10,000,000 ordinary shares of Evotec in the form of 20,000,000 ADSs at a price of $ 21.75 per ADS. Each ADS will represent one half of an ordinary share of Evotec. Accordingly, Evotec's share capital, on the basis of Evotec’s articles of association (“Satzung”), will be increased to € 173,914,741,00 by issuing 10,000,000 shares from the authorized capital (“Genehmigtes Kapital 2021”) under exclusion of subscription rights of the existing shareholders (taking into account the subscription shares issued to date from conditional capital (“Bezugsaktien”), the actual share capital will then amount to € 175,110,695).

Evotec SE: Positive Phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough
Hamburg, Germany, August 3, 2021

Evotec SE announces that the Company has been informed by Bayer about positive Phase IIb results from a clinical trial evaluating the efficacy and safety of the investigational P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic cough. The underlying molecule is a P2X3 receptor antagonist in Bayer’s clinical development pipeline originating from a former Evotec/Bayer multi-target research alliance. The primary efficacy outcome was met showing a statistically significant improvement in 24-hour cough counts per hour (average hourly cough frequency based on 24-hour sound recordings) over placebo after 12 weeks of treatment. The data showed a favourable safety and tolerability profile.

Evotec SE Announces Confidential Submission of Draft Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a Proposed Offering of American Depositary Shares
Hamburg, Germany, August 2, 2021

Evotec SE announces that it confidentially submitted a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed offering and sale in the United States of shares of Evotec represented by American Depositary Shares. The Registration Statement has not yet become effective and the final number of ADSs to be offered and their price have not yet been determined.

Chairman of the Supervisory Board of Evotec to resign from office effective as of the end of the Annual General Meeting on 15 June 2021
Hamburg, Germany, April 23, 2021

Evotec SE announces that today the Chairman of the Supervisory Board, Prof. Dr Wolfgang Plischke, has informed the Company of his decision to resign from his office in the Supervisory Board of Evotec SE effective as of the end of the Annual General Meeting on 15 June 2021 due to personal reasons. Prof. Dr Plischke has been serving in the Supervisory Board as Chairman since 2014.

2020
Mubadala Investment Company and Novo Holdings A/S invest € 250 million in Evotec SE
Hamburg, October 13, 2020

Evotec SE today announced that it resolved on a capital increase from its authorised capital without pre-emptive rights against cash. Evotec will issue a total of 11,478,315 new shares to Mubadala Investment Company and Novo Holdings A/S.

Evotec SE: Increase of profitability guidance for financial year 2019
Hamburg, January 20, 2020

Evotec SE today announced an increase in its profitability guidance for the financial year 2019 after the preliminary completion of the latest evaluation of the Company's financial performance.

2019
Ad hoc: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough
Hamburg, Germany, July 25, 2019

Evotec SE announced today that the Company has been informed by Bayer about positive Phase IIa results from a study surveying the safety, efficacy and dosage of the compound BAY1817080 in refractory chronic cough. 

Ad hoc: Evotec SE to acquire Just Biotherapeutics, Inc.
Hamburg, Germany, May 20, 2019

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”) based in Seattle, WA, USA for up to US$ 90 m (approx. € 81 m; €/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years. The acquisition of 100% of the issued and outstanding equity interests of the company will be paid in cash.

2018
Ad hoc: Evotec AG increases its profitability guidance for 2018
Hamburg, Germany, December 19, 2018

Evotec AG today announced that it increases its profitability guidance for the current year after completing its latest financial evaluation. The Company now expects adjusted Group EBITDA to increase by more than 45% (previously: Improve by approx. 30%) in 2018 compared to last year (2017: € 58.4 m). This mainly results from Evotec’s strong business performance leading to increased margin contribution, important scientific milestone achievements in the fourth quarter of 2018 as well as increased other operating income due to e.g. research & development (“R&D”) tax credits in the second half of 2018.

Ad hoc: Evotec and Celgene enter into strategic oncology partnership
Hamburg, Germany, May 21, 2018

Evotec AG announced today that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.

Ad hoc: Evotec AG plans conversion into European Company (SE)
Hamburg, Germany, March 27, 2018

Evotec AG today decided to begin preparations for legal conversion of the Company into a European Company (Societas Europaea, SE). The proposal, which has already been approved by the Supervisory Board, will be put to a vote at this year’s Annual General Meeting on 20 June 2018.

Ad hoc: Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform
Hamburg, Germany, March 8, 2018
Evotec AG today announced that Evotec and Sanofi have entered into exclusive negotiations to accelerate infectious disease research and development through a new open innovation platform led by Evotec.
2017
Ad hoc: Evotec AG to acquire Aptuit
Hamburg, Germany, July 30, 2017

Evotec AG today announced that it has entered into a definitive agreement with Aptuit Holdings LLC ("Aptuit") under which Evotec will acquire all operational business of Aptuit for $ 300 m (approx. EUR 256 m) to combine the businesses and expand Evotec's role as leading player in integrated outsourced drug discovery and development solutions.

Ad hoc: Novo A/S becomes new long-term strategic shareholder in Evotec
Hamburg, Germany, February 9, 2017

Evotec AG today announced that it resolved on a capital increase from its authorised capital against cash.

2016
Ad hoc: Evotec and Celgene enter into drug discovery collaboration for neurodegenerative diseases
Hamburg, Germany, December 15, 2016

Evotec AG announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. Initial disease areas of focus will include Amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple other neurodegenerative disorders.

Ad hoc: Evotec AG announces its intent to acquire Cyprotex PLC
Hamburg, Germany, October 26, 2016

Evotec AG today announced that it has made an offer to acquire Cyprotex PLC (AIM Listing: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in UK. The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016.

Ad hoc: Evotec AG increases its profitability guidance for 2016
Hamburg, Germany, July 19, 2016

Evotec AG today announced that, in the context of the half year results published on 10 August 2016, it increases its financial guidance for the current year.

2015
Evotec AG increases its revenue guidance for 2015
Hamburg, Germany, September 15, 2015

Evotec AG today announced that it increases its financial guidance for the current year.

Evotec's partner Roche provides initial update from Phase IIb trial in Alzheimer's disease
Hamburg, Germany, June 30, 2015
30 June 2015 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) was updated today by its partner Roche (SIX: RO, ROG; OTCQX: RHHBY) on the initial results of the Phase IIb ...
Evotec and Sanofi sign definitive agreement for major multi-component strategic alliance
Hamburg, Germany, March 20, 2015
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced the signing of a definitive agreement for a major multi-component strategic alliance over the next five ...
2014
Evotec and Sanofi enter into exclusive negotiations for a major multi-component strategic collaboration
, December 2, 2014
Hamburg, Germany - 02 December 2014: Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component ...
Evotec announces update on DiaPep277®
Hamburg, Germany, September 8, 2014

Evotec AG was informed that US company Hyperion Therapeutics, Inc. is terminating the development of DiaPep277(R) for newly diagnosed Type 1 diabetes.

2013
Evotec AG: Results of pre-clinical studies lead to reduction in revenues, nevertheless profitable and more than EUR 90 m cash for 2013 confirmed
Hamburg, Germany, December 13, 2013

Evotec AG today announced that it is adjusting its guidance regarding Group revenues.

Evotec raises EUR 30 m from Biotechnology Value Fund
Hamburg, Germany, August 31, 2013
Hamburg, Germany, 31 August 2013 - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a capital increase against cash contribution by issuing 11,818,613 new shares to Biotechnology ...
Evotec to realign Discovery Chemistry Operations
Hamburg, Germany, July 8, 2013
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it will close its Chemistry Operations in Thane, India. All chemistry efforts will now be performed ...
2012
Evotec announces NMDA antagonist license agreement
Hamburg, Germany, December 17, 2012
Hamburg, Germany - 17 December 2012: Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it has entered into a license agreement with Janssen Pharmaceuticals, Inc. ...
Shifted Milestone Income Leads to Reduction in Operating Income Guidance for the Fiscal Year 2012
Hamburg, Germany, October 19, 2012

Evotec AG  today announced that it is adjusting its guidance regarding profitability on operating income for the fiscal year 2012.

Evotec and Bayer enter into multi-target alliance to fight endometriosis
Hamburg, Germany, October 1, 2012

Evotec AG that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.

CureBeta, a collaboration between Evotec AG and Harvard University enters strategic alliance with Janssen Pharmaceuticals
Hamburg, Germany, July 10, 2012

Evotec AG today announced that it has entered into a license and collaboration agreement with Janssen Pharmaceuticals, Inc. with a particular focus on the regeneration of insulin- producing beta cells.

2011
Ad hoc: Evotec and Roche agree to develop compound that could slow the progression of Alzheimer’s disease
Hamburg, Germany, September 5, 2011

Evotec AG and Roche AG today announced that they have entered into an exclusive world-wide license agreement for the development and commercialisation of Evotec’s MAO-B inhibitor to treat Alzheimer’s disease.

Ad hoc:Evotec acquires compound management business from Galapagos
Hamburg, Germany, June 1, 2011
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, TecDAX, ISIN: DE 000 566480 9) and Galapagos NV (Euronext: GLPG) today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, ...
Ad hoc: Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated
Hamburg, Germany, May 18, 2011
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, TecDAX, ISIN: DE 000 566480 9) and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type ...
Ad hoc:Evotec acquires Kinaxo, expanding its drug discovery platform with cutting-edge technologies
Hamburg, Germany, February 9, 2011
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based ...
2010
Ad hoc:Evotec announces metabolic disease alliance with MedImmune
Hamburg, Germany, December 15, 2010
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with ...
Ad hoc:Strong Milestone Income Leads to Profitable First Half for Evotec and Increase in Revenue Guidance for the Fiscal Year 2010
Hamburg, Germany, August 12, 2010
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today reported financial results and corporate updates for the first half of 2010. Group revenues grew significantly by ...
Ad hoc: Evotec Strengthens Discovery Alliance Business through Acquisition of DeveloGen
Hamburg, Germany, July 14, 2010
Hamburg, Germany - 14 July 2010 - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company ...
2009
Ad hoc: Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration
Hamburg, Germany, November 9, 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480, TecDAX) today announced that it has extended the research collaboration with Boehringer Ingelheim for a further 4 years. The collaboration ...
Ad hoc: Evotec starts Phase I with EVT 103, an NR2B-selective NMDA receptor antagonist
Hamburg, Germany, September 8, 2009
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today the Phase I clinical study initiation for EVT 103, a small molecule NR2B-selective NMDA receptor antagonist. EVT 103 is a next generation ...
Ad hoc: Evotec Accelerates Growth Strategy of its Discovery Alliance Business with Acquisition of Indian RSIPL
Hamburg, Germany, August 6, 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) and DIL Limited, India, announced today the signing of a definitive agreement to acquire a 70% controlling majority stake of the drug ...
Ad hoc: Evotec Announces the Successful Completion of the First Phase I Study with EVT 401
Hamburg, Germany, June 29, 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced the successful completion of the first Phase I study with its P2X7 receptor antagonist EVT 401. EVT 401 is a small molecule ...
Ad hoc: Evotec Acquires Zebrafish Screening Operations of Summit Corporation
Hamburg, Germany, May 7, 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that the Company will acquire the zebrafish screening operations of Summit Corporation plc, including operations in Abingdon, ...
Ad hoc: Evotec to Re-engineer Drug Discovery and Development Operations
Hamburg, Germany, May 5, 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that in the context of its Evotec 2012 - Action Plan to Focus and Grow, the Company is re-engineering its drug discovery and ...
Ad hoc: Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302
Hamburg, Germany, April 14, 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced the results of a Phase II proof-of-concept study investigating the potential of EVT 302, a reversible and highly selective ...
Ad hoc: Evotec Restructures and Implements \"Evotec 2012 - Action Plan to Focus and Grow\"
, March 27, 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today decided that it will restructure to focus on core value programs and significantly reduce its operating costs. This follows the ...
Ad hoc: Evotec and Roche to Develop EVT 101 for Treatment-Resistant Depression
, March 9, 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) and Roche announced today that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with ...
Ad hoc: Evotec Appoints Dr. Werner Lanthaler as Chief Executive Officer
Hamburg, Germany, March 6, 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced today the appointment of Dr. Werner Lanthaler as Chief Executive Officer of the Company, effective immediately. In his previous ...
2008
Ad hoc: Jörn Aldag resigns as CEO of Evotec AG
Hamburg, Germany, December 10, 2008
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced today that Jörn Aldag will resign from his position as President & Chief Executive Officer of Evotec. The resignation will ...
Ad hoc: Renovis Stockholders Approve Acquisition by Evotec
Hamburg, Germany, May 1, 2008
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that the stockholders of Renovis, Inc. (NASDAQ: RNVS) approved the adoption of the merger agreement with Evotec at a special ...
2007
Ad hoc: Evotec Reports Positive Top-Line Results in Phase II Study with EVT 201 in Elderly Insomniacs with Daytime Sleepiness
Hamburg, Germany, October 16, 2007
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today completed the top-line analysis of its double-blind, placebo-controlled, parallel group design phase II trial of EVT 201 1.5 mg and 2.5 ...
Ad hoc: Evotec to Acquire Renovis, Seek NASDAQ Listing
Hamburg, Germany, September 19, 2007
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) and Renovis, Inc., South San Francisco, California, US, today announced that they have entered into a definitive agreement under which Evotec ...
Ad hoc: Evotec Sells its Chemical Development Business to Aptuit for GBP 31.5m (approx. EUR 46.4m) in Cash
Hamburg, Germany, September 10, 2007
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it has sold its Chemical Development Business to Aptuit, Inc., Greenwich, CT, US, for approximately EUR 46.4 m in cash. ...
Ad hoc: Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
Hamburg, Germany, June 4, 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced today positive top-line results from its first phase II clinical trial of EVT 201 in patients with ...
Ad hoc: Evotec to Acquire Neuro3d
Hamburg, Germany, March 29, 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced the acquisition of all shares of Neuro3d S.A., Mulhouse, France, with all assets contained ...
2006
Hugin Ad hoc announcement according to § 15 WpHG: Acquisition: Evotec AG: PerkinElmer to Acquire Evotec Technologies
Hamburg, Germany, December 1, 2006
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that the Company has signed a definitive agreement with PerkinElmer pursuant to which PerkinElmer will acquire Evotec ...
Hugin Ad hoc announcement according to § 15 WpHG: Misc. matters: Evotec AG: Evotec Initiates Phase II Clinical Trial with EVT 201 for the Treatment of Insomnia
Hamburg, Germany, September 21, 2006
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today initiated a Phase II clinical trial with EVT 201 for the treatment of insomnia under a US IND. This US, ...
Hugin Ad hoc announcement according to § 15 WpHG: Misc. strategic decisions: Evotec AG: Evotec Discontinues EVT 301 Development Programme
Hamburg, Germany, September 13, 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today reported that during the one month safety and tolerability study with EVT 301 in young and elderly ...
Ad hoc: Evotec Reports Preliminary Q2 Summary Results
Hamburg, Germany, July 24, 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today reported preliminary results of the second quarter 2006. Group revenues grew 2% over Q2 2005, to EUR ...
Ad hoc: Offering of Evotec Shares Successfully Completed
Hamburg, Germany, April 27, 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced that today 5,228,701 Evotec shares were successfully placed by DZ BANK AG, Frankfurt, as Sole Lead ...
Ad hoc: Evotec Intends to Raise Approximately EUR 18 Million in a Share Capital Increase
Hamburg, Germany, and Oxford, UK, April 26, 2006
  Hamburg, Germany, and Oxford, UK, 26.04.2006 Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that the Management Board and Supervisory Board have decided to increase ...
Ad hoc: Evotec Exceeds Revenue Target for 2005
Hamburg, Germany, January 4, 2006
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it exceeded its revenue target for the financial year 2005 of "up to 5%" growth over 2004 (2004: EUR 72.7 million). ...
2005
Ad hoc: Evotec OAI Announces In-licensing of a Compound
Hamburg, Germany, March 18, 2005
Hamburg, Germany | Oxford, UK - Evotec OAI AG announces today that its soon to be 100%-owned subsidiary Evotec Neurosciences GmbH (ENS) has in-licensed a compound from an unnamed third party which has safely completed a ...
Ad hoc: Evotec Acquires ENS and Secures € 47m in Cash to Develop CNS Pipeline
Hamburg, Germany, March 6, 2005
Evotec OAI AG (Evotec) today announces the acquisition of the outstanding 78% of Evotec Neurosciences (ENS Holdings, Inc., ENS) not already owned by Evotec. ENS discovers and develops therapeutics for the treatment of Alzheimer's ...
2004
Ad hoc: Evotec OAI Updates Guidance for 2004 and Provides Preliminary Third Quarter Revenues
Hamburg, Germany, October 20, 2004
For the first nine months of 2004 Evotec OAI's (WKN 566480) revenues reached EUR 47.4m (2003: EUR 56.7m). In the third quarter, revenues amounted to EUR 16.1m, down 26% over Q3 of the previous year (2003: EUR 21.9m). The decline ...
Ad Hoc: Evotec OAI Intends to Increase its Share Capital
Hamburg, Germany, July 14, 2004
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that the Management Board decided to increase its share capital against contribution in cash from authorised capital, ...
Ad hoc: Offering of Evotec OAI Shares Successfully Completed
Hamburg, Germany, July 14, 2004
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announced that today 2,500,000 Evotec OAI shares were successfully placed by Sal. Oppenheim as Global Co-ordinator and bookrunner. The new ...

 

 

TOP